Janssen Launches New Research Platforms For Disease Prevention
On February 12, 2015, Janssen Research & Development, LLC (Janssen) announced the launch of three new research platforms—focused on disease prevention, disease interception, and the microbiome. The new teams will collaborate closely with Janssen’s five Therapeutic Areas as well as external partners. The goal is to deliver the next generation of transformational medical innovation and change the way diseases are managed.
Janssen Research & Development, LLC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen’s focus areas include oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. The three new platforms . . .
